MeSH term
Frequency | Condition_Probility | Chromogranins/secretion | 2 | 66.0 |
Comparative Study | 46 | 0.0 |
Humans | 274 | 0.0 |
Octreotide/pharmacology | 2 | 8.0 |
Research Support, Non-U.S. Gov't | 146 | 0.0 |
Animals | 58 | 0.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 49 | 0.0 |
Adult | 100 | 0.0 |
Aged | 107 | 0.0 |
Chromogranins/*blood | 53 | 96.0 |
Female | 135 | 0.0 |
Immunoradiometric Assay | 2 | 1.0 |
Male | 165 | 0.0 |
Middle Aged | 122 | 0.0 |
*Adrenalectomy | 2 | 18.0 |
Analysis of Variance | 7 | 0.0 |
Case-Control Studies | 7 | 0.0 |
Chromatography, High Pressure Liquid | 6 | 0.0 |
Epinephrine/blood | 5 | 4.0 |
Norepinephrine/blood | 5 | 2.0 |
Posture | 2 | 2.0 |
Blotting, Western | 4 | 0.0 |
Cell Differentiation | 20 | 0.0 |
Cell Division | 7 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 8 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Tumor Cells, Cultured | 17 | 0.0 |
Tumor Markers, Biological/*metabolism | 4 | 0.0 |
Biological Markers/blood | 3 | 0.0 |
Chronic Disease | 3 | 0.0 |
Follow-Up Studies | 16 | 0.0 |
Predictive Value of Tests | 10 | 0.0 |
Prognosis | 28 | 0.0 |
Severity of Illness Index | 4 | 0.0 |
Survival Analysis | 6 | 0.0 |
Chromogranins/immunology | 2 | 50.0 |
Histocytochemistry | 2 | 0.0 |
Mice | 18 | 0.0 |
Mice, Nude | 7 | 0.0 |
Chromogranins/*biosynthesis | 5 | 83.0 |
Neurosecretory Systems/pathology | 3 | 27.0 |
Staining and Labeling/methods | 3 | 2.0 |
Androgens/*pharmacology | 2 | 3.0 |
Disease Progression | 8 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 7 | 0.0 |
Gastrins/*blood | 4 | 9.0 |
Gene Expression Regulation, Neoplastic | 6 | 0.0 |
Immunohistochemistry | 80 | 0.0 |
Longitudinal Studies | 2 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
Neoplasm Staging | 16 | 0.0 |
Peptide Fragments/*blood | 2 | 2.0 |
Phenotype | 4 | 0.0 |
Prostate-Specific Antigen/*blood | 6 | 6.0 |
Prostatic Neoplasms/*pathology | 5 | 4.0 |
Tumor Markers, Biological/*analysis | 18 | 1.0 |
Up-Regulation | 2 | 0.0 |
Antineoplastic Agents, Hormonal/therapeutic use | 4 | 8.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Phosphopyruvate Hydratase/blood | 6 | 40.0 |
Prostate-Specific Antigen/blood | 10 | 11.0 |
ROC Curve | 3 | 1.0 |
Sensitivity and Specificity | 24 | 0.0 |
Fetal Blood/*metabolism | 2 | 4.0 |
Infant, Newborn | 8 | 0.0 |
Pregnancy | 6 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Transfection | 5 | 0.0 |
Chromogranins/*analysis/blood | 2 | 100.0 |
Carcinoma, Small Cell/chemistry/*pathology | 2 | 50.0 |
Chromogranins/analysis | 21 | 41.0 |
Phosphopyruvate Hydratase/analysis | 6 | 7.0 |
Retrospective Studies | 14 | 0.0 |
Synaptophysin/analysis | 5 | 14.0 |
English Abstract | 16 | 0.0 |
Adolescent | 29 | 0.0 |
Aged, 80 and over | 42 | 0.0 |
Neurosecretory Systems/*pathology | 6 | 50.0 |
Serotonin/analysis | 5 | 20.0 |
Chromogranins/*analysis | 31 | 77.0 |
Chromogranins/analysis/*blood | 2 | 100.0 |
Diagnosis, Differential | 8 | 0.0 |
Treatment Outcome | 8 | 0.0 |
Tumor Markers, Biological/analysis/*blood | 2 | 28.0 |
Immunoassay | 2 | 0.0 |
Neoplasm Staging/*methods | 2 | 5.0 |
Biopsy | 2 | 0.0 |
Neurosecretory Systems/physiology | 3 | 21.0 |
Prospective Studies | 10 | 0.0 |
Androgen Antagonists/therapeutic use | 2 | 9.0 |
Carcinoma/*pathology | 2 | 3.0 |
Tumor Markers, Biological/*blood | 25 | 5.0 |
Amyloid beta-Protein Precursor/metabolism | 2 | 5.0 |
Chromogranins/metabolism | 13 | 43.0 |
Peptide Fragments/metabolism | 4 | 1.0 |
Rats | 15 | 0.0 |
In Situ Hybridization | 7 | 0.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Tumor Markers, Biological/genetics/*metabolism | 3 | 8.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 2 | 1.0 |
Reference Values | 6 | 0.0 |
Adenoma/metabolism/pathology | 3 | 10.0 |
Carcinoid Tumor/*metabolism/pathology | 4 | 50.0 |
Insulinoma/metabolism/pathology | 2 | 66.0 |
Antineoplastic Agents, Hormonal/*therapeutic use | 4 | 5.0 |
Chemotherapy, Adjuvant | 2 | 0.0 |
Cohort Studies | 4 | 0.0 |
Disease-Free Survival | 4 | 0.0 |
Estrogen Receptor alpha | 2 | 0.0 |
Adenocarcinoma/*chemistry/pathology | 2 | 4.0 |
Immunoenzyme Techniques | 17 | 0.0 |
Receptors, Somatostatin/*analysis | 2 | 25.0 |
Somatostatin/analysis | 4 | 7.0 |
Child | 12 | 0.0 |
Proprotein Convertase 2 | 3 | 15.0 |
Proprotein Convertases | 5 | 10.0 |
Chromogranins/*metabolism | 16 | 69.0 |
Immunohistochemistry/methods | 3 | 0.0 |
Neurons/metabolism | 2 | 0.0 |
Neuropsychological Tests | 2 | 0.0 |
Time Factors | 9 | 0.0 |
Tumor Markers, Biological/blood | 6 | 3.0 |
Molecular Weight | 5 | 0.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Prostatectomy | 3 | 3.0 |
Tumor Markers, Biological | 5 | 1.0 |
Microscopy, Electron | 7 | 0.0 |
Amino Acid Sequence | 23 | 0.0 |
Catecholamines/*metabolism | 2 | 3.0 |
Chromatography, Affinity | 2 | 0.0 |
Molecular Sequence Data | 27 | 0.0 |
PC12 Cells | 4 | 1.0 |
Peptide Fragments/*metabolism | 2 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 32 | 0.0 |
Phosphopyruvate Hydratase/*blood | 5 | 29.0 |
Neurosecretory Systems/metabolism | 3 | 21.0 |
Tumor Markers, Biological/metabolism | 4 | 1.0 |
Antibody Specificity | 4 | 0.0 |
Chromogranins/chemistry/immunology/*metabolism | 3 | 100.0 |
Glucagon/metabolism | 2 | 7.0 |
Somatostatin/metabolism | 3 | 6.0 |
Chromogranins/biosynthesis | 3 | 60.0 |
Statistics, Nonparametric | 4 | 0.0 |
Proteins/*genetics | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Hypertension/blood | 2 | 11.0 |
Immunoradiometric Assay/*methods | 2 | 28.0 |
Pancreatic Neoplasms/blood/diagnosis | 2 | 50.0 |
Carcinoid Tumor/blood | 3 | 100.0 |
Gastrinoma/blood | 2 | 100.0 |
Liver Neoplasms/secondary | 2 | 3.0 |
Multiple Endocrine Neoplasia Type 1/blood | 2 | 100.0 |
Cattle | 16 | 0.0 |
Chromogranins/*pharmacology | 4 | 80.0 |
Peptide Fragments/*pharmacology | 4 | 2.0 |
Recombinant Proteins/pharmacology | 3 | 0.0 |
Phosphopyruvate Hydratase/biosynthesis | 2 | 40.0 |
Chromogranins/immunology/*metabolism | 3 | 60.0 |
Immune Sera | 3 | 1.0 |
*Protein Processing, Post-Translational | 3 | 1.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Basement Membrane/cytology | 2 | 28.0 |
Cell Count | 3 | 0.0 |
Gestational Age | 2 | 0.0 |
Immunohistochemistry/*methods | 2 | 2.0 |
Neurosecretory Systems/*cytology | 6 | 54.0 |
Sudden Infant Death/*pathology | 2 | 16.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Lymphatic Metastasis | 4 | 0.0 |
Survival Rate | 11 | 0.0 |
Antibodies, Monoclonal | 4 | 0.0 |
Immunoblotting | 4 | 0.0 |
*Tumor Markers, Biological | 2 | 1.0 |
Adenocarcinoma/chemistry/pathology | 2 | 11.0 |
Bone Neoplasms/secondary | 2 | 4.0 |
*Multienzyme Complexes | 2 | 2.0 |
Tumor Markers, Biological/*biosynthesis | 2 | 2.0 |
Ki-67 Antigen/analysis | 2 | 0.0 |
Neoadjuvant Therapy | 2 | 5.0 |
Fatal Outcome | 3 | 0.0 |
Age Factors | 2 | 0.0 |
Neoplasms/*blood | 2 | 4.0 |
Sex Factors | 2 | 0.0 |
Lung Neoplasms/metabolism | 3 | 8.0 |
Neuroblastoma/metabolism | 2 | 3.0 |
Neuroendocrine Tumors/*metabolism | 3 | 33.0 |
Pheochromocytoma/metabolism | 2 | 28.0 |
Protein Structure, Tertiary | 5 | 0.0 |
Thyroid Neoplasms/metabolism | 3 | 15.0 |
Carcinoma, Small Cell/*chemistry/mortality | 2 | 100.0 |
Lung Neoplasms/*chemistry/mortality | 2 | 50.0 |
Base Sequence | 14 | 0.0 |
Child, Preschool | 8 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
Infant | 9 | 0.0 |
Pedigree | 3 | 0.0 |
Enterochromaffin Cells/metabolism/pathology | 2 | 100.0 |
Hyperplasia | 5 | 1.0 |
Chromogranins/genetics/metabolism | 2 | 66.0 |
Pancreatic Neoplasms/*blood | 2 | 22.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Genetic Markers | 3 | 0.0 |
Nuclear Proteins/*analysis | 2 | 1.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
Cell Line | 10 | 0.0 |
Chromogranins/*physiology | 2 | 100.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Calcitonin/analysis | 5 | 20.0 |
Species Specificity | 4 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Pancreatic Hormones/metabolism | 2 | 40.0 |
Stomach Neoplasms/blood | 2 | 40.0 |
Cross-Sectional Studies | 3 | 0.0 |
Gastric Acid/*secretion | 2 | 3.0 |
Helicobacter pylori/isolation & purification | 2 | 15.0 |
Chromatography, Gel | 5 | 0.0 |
Radioimmunoassay | 13 | 0.0 |
Octreotide/*therapeutic use | 3 | 8.0 |
Transplantation, Heterologous | 2 | 0.0 |
Neurosecretory Systems/metabolism/*pathology | 3 | 60.0 |
Neoplasm Transplantation | 4 | 0.0 |
Orchiectomy | 2 | 1.0 |
Prostatic Neoplasms/metabolism/*pathology | 2 | 2.0 |
Blotting, Northern | 8 | 0.0 |
Gene Expression | 7 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Serotonin/metabolism | 4 | 5.0 |
Carcinoma, Medullary/blood | 2 | 66.0 |
Thyroid Neoplasms/blood | 2 | 15.0 |
Antibodies | 2 | 0.0 |
Rabbits | 2 | 0.0 |
Neuroendocrine Tumors/*chemistry | 2 | 50.0 |
Multivariate Analysis | 3 | 0.0 |
Cervix Neoplasms/metabolism/*pathology | 2 | 22.0 |
Gastric Mucosa/metabolism/pathology | 2 | 9.0 |
Blotting, Southern | 4 | 0.0 |
Chromogranins/*genetics | 9 | 64.0 |
Cells, Cultured | 6 | 0.0 |
Peptide Fragments/pharmacology | 2 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism | 2 | 0.0 |
Neuroendocrine Tumors/pathology | 2 | 50.0 |
Androgen Antagonists/*therapeutic use | 3 | 8.0 |
Biological Markers | 3 | 0.0 |
Antibodies, Monoclonal/immunology | 3 | 0.0 |
Cell Transformation, Neoplastic/pathology | 2 | 4.0 |
Chromogranins/*analysis/genetics/immunology | 2 | 100.0 |
Chromogranins/*analysis/immunology | 3 | 75.0 |
Lymphatic Metastasis/pathology | 3 | 4.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Stomach Neoplasms/*pathology | 2 | 4.0 |
Immunoradiometric Assay/methods | 2 | 14.0 |
Carcinoma, Small Cell/blood | 2 | 33.0 |
Hydroxyindoleacetic Acid/urine | 4 | 36.0 |
Chromogranins/blood | 3 | 50.0 |
Ubiquitin Thiolesterase | 2 | 1.0 |
Norepinephrine/*blood | 3 | 5.0 |
Pancreatic Hormones/*blood | 2 | 22.0 |
Thyrotropin/analysis | 2 | 16.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Pentagastrin/diagnostic use | 2 | 18.0 |
Proton Pumps/*antagonists & inhibitors | 2 | 10.0 |
Antibodies, Monoclonal/diagnostic use | 3 | 0.0 |
Aging/*pathology | 2 | 7.0 |
Pancreatic Hormones/*metabolism | 2 | 50.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 3 | 0.0 |
Swine | 5 | 0.0 |
Cross Reactions | 3 | 0.0 |
Chromogranins/*chemistry | 2 | 66.0 |
Depression, Chemical | 2 | 1.0 |
In Vitro | 4 | 0.0 |
Myocardial Contraction/*drug effects | 2 | 8.0 |
Peptide Fragments/chemistry/*pharmacology | 2 | 6.0 |
Potassium/pharmacology | 2 | 3.0 |
Sequence Alignment | 2 | 0.0 |
Neoplasms, Hormone-Dependent/blood/*drug therapy/pathology | 2 | 100.0 |
Prostatectomy/methods | 2 | 28.0 |
RNA, Messenger/genetics | 6 | 0.0 |
Oligonucleotide Probes | 2 | 0.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Neuroendocrine Tumors/blood | 2 | 100.0 |
*Chromosome Mapping | 2 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Pancreatic Hormones/*analysis | 3 | 75.0 |
Tumor Markers, Biological/analysis | 6 | 0.0 |
Ionomycin/pharmacology | 2 | 0.0 |
Kinetics | 5 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
Adrenal Medulla/metabolism | 2 | 14.0 |
Cloning, Molecular | 5 | 0.0 |
Vasoconstriction/drug effects | 2 | 5.0 |
Neurosecretory Systems/*metabolism | 3 | 20.0 |
Signal Transduction | 2 | 0.0 |
Prostate-Specific Antigen/analysis | 2 | 4.0 |
Neoplasm Invasiveness | 3 | 0.0 |
Cerebrovascular Disorders/*metabolism/pathology | 2 | 100.0 |
Anus/*cytology | 2 | 100.0 |
Peptide YY | 2 | 1.0 |
Peptides/metabolism | 3 | 1.0 |
Endothelins/pharmacology | 2 | 20.0 |
Muscle Contraction/drug effects | 2 | 2.0 |
Rana esculenta | 2 | 33.0 |
Chromogranins/blood/*secretion | 3 | 100.0 |
Exercise | 2 | 1.0 |
Adrenal Gland Neoplasms/*diagnosis | 2 | 50.0 |
Pheochromocytoma/*diagnosis | 2 | 66.0 |
Immune Sera/immunology | 2 | 1.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Hela Cells | 2 | 0.0 |
Nucleic Acid Conformation | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Protein Precursors/metabolism | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Adenoma/*pathology | 2 | 9.0 |
Growth Hormone/analysis | 2 | 18.0 |
Prolactin/analysis | 2 | 11.0 |
Stimulation, Chemical | 2 | 0.0 |
Sex Characteristics | 2 | 0.0 |
Neurons/*metabolism | 2 | 0.0 |
Alzheimer Disease/metabolism/*pathology | 2 | 6.0 |
Brain/metabolism/*pathology | 2 | 6.0 |
Chromogranins/immunology/metabolism | 2 | 100.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Alleles | 2 | 0.0 |
DNA/genetics | 5 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
DNA Probes | 2 | 0.0 |
Receptors, Estrogen/genetics | 2 | 3.0 |
Chromogranins/analysis/*metabolism | 2 | 100.0 |
Chromogranins/*cerebrospinal fluid | 2 | 100.0 |
Sympathetic Nervous System/metabolism | 2 | 20.0 |
Somatostatin/pharmacology | 2 | 4.0 |
Endocrine Gland Neoplasms/metabolism/*pathology | 2 | 100.0 |
Tissue Distribution | 2 | 0.0 |
Nucleic Acid Hybridization | 6 | 0.0 |
Nerve Tissue Proteins/*secretion | 2 | 66.0 |
Neurosecretory Systems/chemistry/*pathology | 2 | 66.0 |
Antigens, CD57/analysis | 2 | 4.0 |
*Chromosomes, Human, Pair 14 | 2 | 1.0 |
Nerve Tissue Proteins/*genetics | 6 | 0.0 |
Mutation | 2 | 0.0 |
Nerve Tissue Proteins/*analysis | 4 | 5.0 |
Cytoplasmic Granules/*ultrastructure | 2 | 18.0 |
Microscopy, Confocal | 2 | 0.0 |
Antineoplastic Agents, Hormonal/administration & dosage | 2 | 33.0 |
Flutamide/administration & dosage | 2 | 40.0 |
Randomized Controlled Trials | 2 | 0.0 |
